Details of the Drug Formulations

General Information of Drug (ID: DMIYDT4)

Drug Name
Cabozantinib Drug Info
Synonyms Cabometyx; Cometriq
Indication
Disease Entry ICD 11 Status REF
Medullary thyroid gland carcinoma Approved [1]
Thyroid cancer 2D10 Approved [2]
Ovarian cancer 2C73 Phase 2 [2]
Cross-matching ID
PubChem CID
25102847
ChEBI ID
CHEBI:72317
CAS Number
849217-68-1
TTD ID
D0IQ6P
INTEDE ID
DR0254
ACDINA ID
D00087

Full List of Drug Formulations Containing This Drug

Cabozantinib 20 mg capsule
Company Formulation ID FDA Description
Exelixis F03083 Stearic acid; Butyl alcohol; Isopropyl alcohol; Ammonia; Ferrosoferric oxide; Propylene glycol; Titanium dioxide; Croscarmellose sodium; Silicon dioxide; Cellulose, microcrystalline; Gelatin; Shellac; Sodium starch glycolate type a potato
------------------------------------------------------------------------------------
Cabozantinib S-Malate eq 80mg base capsule
Company Formulation ID FDA Description
Exelixis F23394 Silicified Microcrystalline Cellulose; Croscarmellose Sodium; Sodium Starch Glycolate; Fumed Silica; Stearic Acid; Shellac Glaze; Black Iron Oxide; N-Butyl Alcohol; Isopropyl Alcohol; Propylene Glycol; Ammonium Hydroxide; Red Iron Oxide; Titanium Dioxide
------------------------------------------------------------------------------------
Cabozantinib S-Malate eq 20mg base capsule
Company Formulation ID FDA Description
Exelixis F23395 Silicified Microcrystalline Cellulose; Croscarmellose Sodium; Sodium Starch Glycolate; Fumed Silica; Stearic Acid; Shellac Glaze; Black Iron Oxide; N-Butyl Alcohol; Isopropyl Alcohol; Propylene Glycol; Ammonium Hydroxide; Titanium Dioxide
------------------------------------------------------------------------------------
Cabozantinib S-Malate eq 20mg base tablet
Company Formulation ID FDA Description
Exelixis F23947 Microcrystalline Cellulose; Lactose Anhydrous; Hydroxypropyl Cellulose; Croscarmellose Sodium; Colloidal Silicon Dioxide; Magnesium Stearate; Hypromellose; Titanium Dioxide; Triacetin; Iron Oxide Yellow
------------------------------------------------------------------------------------
Cabozantinib S-Malate eq 40mg base tablet
Company Formulation ID FDA Description
Exelixis F23948 Microcrystalline Cellulose; Lactose Anhydrous; Hydroxypropyl Cellulose; Croscarmellose Sodium; Colloidal Silicon Dioxide; Magnesium Stearate; Hypromellose; Titanium Dioxide; Triacetin; Iron Oxide Yellow
------------------------------------------------------------------------------------
Cabozantinib S-Malate eq 60mg base tablet
Company Formulation ID FDA Description
Exelixis F23949 Microcrystalline Cellulose; Lactose Anhydrous; Hydroxypropyl Cellulose; Croscarmellose Sodium; Colloidal Silicon Dioxide; Magnesium Stearate; Hypromellose; Titanium Dioxide; Triacetin; Iron Oxide Yellow
------------------------------------------------------------------------------------
Cabozantinib 20 mg tablet
Company Formulation ID FDA Description
Exelixis F03084 Anhydrous lactose; Magnesium stearate; Ferric oxide yellow; Titanium dioxide; Triacetin; Croscarmellose sodium; Silicon dioxide; Cellulose, microcrystalline; Hydroxypropyl cellulose (type h); Hypromelloses
------------------------------------------------------------------------------------
Cabozantinib 40 mg tablet
Company Formulation ID FDA Description
Exelixis F03085 Anhydrous lactose; Magnesium stearate; Ferric oxide yellow; Titanium dioxide; Triacetin; Croscarmellose sodium; Silicon dioxide; Cellulose, microcrystalline; Hydroxypropyl cellulose (type h); Hypromelloses
------------------------------------------------------------------------------------
Cabozantinib 60 mg tablet
Company Formulation ID FDA Description
Exelixis F03086 Anhydrous lactose; Magnesium stearate; Ferric oxide yellow; Titanium dioxide; Triacetin; Croscarmellose sodium; Silicon dioxide; Cellulose, microcrystalline; Hydroxypropyl cellulose (type h); Hypromelloses
------------------------------------------------------------------------------------

References

1 Cabozantinib FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5887).